Home | Articles
Published on:April 2016
Indian Journal of Pharmaceutical Education and Research, 2016; 50(2s):S153-S158
Pharmaceutical Research | doi:10.5530ijper.50.2.31

Dexmedetomidine, Application in Pediatrics: Paper Review


Authors and affiliation (s):

María Gabriela Pérez-Guillé1*, Chiharu Murata2, Rosa Eugenia Reyes-Reyes3, Beatríz Pérez-Guillé4, José Bobadilla-Chavez5, Radames Alemon-Medina1, Ismene Corral-G6, Neydi Osnaya-Romero7

1Department Experimental Medicine, Laboratory of Pharmacology, National Institute of Pediatrics, PZ 04530, Mexico City, MEXICO.

2Department Experimental Medicine, Investigation Methodology, National Institute of Pediatrics, PZ 04530, Mexico City, MEXICO.

3Department Experimental Medicine, Cytogenetics Laboratory, National Institute of Pediatrics, PZ 04530, Mexico City, Mexico.

4Department Experimental Medicine, Laboratory of Experimental Surgery, National Institute of Pediatrics, PZ 04530, Mexico City, MEXICO.

5Department Experimental Medicine, Hospital Pharmacy, National Institute of Pediatrics, PZ 04530, Mexico City, Mexico.

6Department Experimental Medicine, Laboratory of Neuro development, National Institute of Pediatrics, PZ 04530, Mexico City, MEXICO.

7Department Experimental Medicine, Unit of support to Clinical Investigation, National Institute of Pediatrics, PZ 04530, Mexico City, MEXICO.

Abstract:

Introduction: Dexmedetomidine is a drug with sedative, hypnotic, and analgesic properties. Its use in adult sedation was approved in 1999. In children, although the use has not been approved, its application by paediatricians is common. The drug offers many advantages in sedative procedures of paediatric patients. First, the half-life is relatively short. Second, it has little or no effect on respiratory management, and lastly, it is well tolerated by intensive care unit patients found with mechanical ventilation. Pharmacokinetics: 93% of the drug bonds with plasma proteins on absorption. Then, it undergoes a rapid phase of distribution with a half-life of 7 min. It has a depuration rate of 15 ml/kg/min, and half-life elimination rate of 2 h. Pharmacodynamics: The drug has antinociceptive action on α-2A adrenergic receptor of the spinal cord. It has hypnotic-sedative action, and inhibitory effect on central noradrenergic transmission. Applications: It is used as a premedication agent with the objective of getting better cooperation of the patient on starting anaesthetic procedures. Adverse reactions: Bradycardia and hypotension. Conclusion: Its use appears to have a promising future in paediatric population; however, it is pertinent that more controlled clinical studies be carried out in order to demonstrate its safety and efficacy.

Key words: Dexmedetomidine, Pharmacokinetic/pharmacodynamic, Paediatric patients, Adverse reaction, Applications.

 




 

Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the Latest Release of Journal Citation Reports (source: Web of Science Data).

 

Impact Factor® as reported in the 2023 Journal Citation Reports® (Clarivate Analytics, 2023): 0.8

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.

DOI HISTORY

IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs